Idorsia Ltd (IDRSF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -255.14 Million CHF | 32.37% |
| 2022 | -802.96 Million CHF | -30.99% |
| 2021 | -613 Million CHF | -49.3% |
| 2020 | -410.58 Million CHF | 14.89% |
| 2019 | -482.42 Million CHF | -30.01% |
| 2018 | -371.07 Million CHF | -4606.68% |
| 2017 | -7.88 Million CHF | 97.56% |
| 2016 | -322.81 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -94.61 Million CHF | 17.45% |
| 2024 Q2 | -97.05 Million CHF | -0.49% |
| 2023 Q1 | -197.59 Million CHF | -2.51% |
| 2023 Q3 | 230.8 Million CHF | 230.39% |
| 2023 Q2 | -177 Million CHF | 10.42% |
| 2023 FY | -543.05 Million CHF | 32.37% |
| 2023 Q4 | -114.6 Million CHF | -149.66% |
| 2022 FY | -802.96 Million CHF | -30.99% |
| 2022 Q4 | -192.75 Million CHF | 6.24% |
| 2022 Q3 | -205.57 Million CHF | 3.07% |
| 2022 Q2 | -212.08 Million CHF | -10.15% |
| 2022 Q1 | -192.54 Million CHF | 15.67% |
| 2021 Q3 | -133.13 Million CHF | -2.61% |
| 2021 Q1 | -121.79 Million CHF | 0.62% |
| 2021 Q2 | -129.74 Million CHF | -6.53% |
| 2021 FY | -613 Million CHF | -49.3% |
| 2021 Q4 | -228.32 Million CHF | -71.5% |
| 2020 Q4 | -122.55 Million CHF | -11.57% |
| 2020 Q2 | -67.17 Million CHF | 39.48% |
| 2020 Q1 | -111 Million CHF | 12.64% |
| 2020 Q3 | -109.84 Million CHF | -63.52% |
| 2020 FY | -410.58 Million CHF | 14.89% |
| 2019 Q2 | -120.57 Million CHF | -1.57% |
| 2019 FY | -482.42 Million CHF | -30.01% |
| 2019 Q4 | -127.06 Million CHF | -9.49% |
| 2019 Q3 | -116.05 Million CHF | 3.75% |
| 2019 Q1 | -118.72 Million CHF | -18.11% |
| 2018 Q3 | -115.23 Million CHF | -42.46% |
| 2018 FY | -371.07 Million CHF | -4606.68% |
| 2018 Q4 | -100.51 Million CHF | 12.77% |
| 2018 Q2 | -80.89 Million CHF | -8.68% |
| 2018 Q1 | -74.42 Million CHF | -205.55% |
| 2017 Q2 | 100.93 Million CHF | 190.51% |
| 2017 Q3 | -68.35 Million CHF | -167.72% |
| 2017 Q4 | 70.51 Million CHF | 203.17% |
| 2017 Q1 | -111.52 Million CHF | 0.0% |
| 2017 FY | -7.88 Million CHF | 97.56% |
| 2016 FY | -322.81 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -7953.123% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -27294.297% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -9610.48% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -1329.624% |
| GB Sciences, Inc. | -1.42 Million USD | -17861.519% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -7393.291% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -115833.896% |
| Skye Bioscience, Inc. | -13.67 Million USD | -1766.214% |
| Zenith Capital Corp. | -8.94 Million USD | -2753.014% |
| Agentix Corp. | -1.37 Million USD | -18499.882% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -4957.902% |
| Biomind Labs Inc. | -1 Million USD | -25171.815% |
| ContraFect Corporation | -56.88 Million USD | -348.496% |
| CSL Limited | 3.7 Billion USD | 106.892% |
| CytoDyn Inc. | -18.05 Million USD | -1312.919% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -13585.32% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -65394.006% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -359.654% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -61309.843% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -16510.473% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -37041.713% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 411.715% |
| SQZ Biotechnologies Company | -75.82 Million USD | -236.492% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -12744.082% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -255.424% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -8850.864% |
| Mesoblast Limited | -84.14 Million USD | -203.213% |
| Marizyme, Inc. | -34.08 Million USD | -648.522% |
| Genus plc | 6.4 Million USD | 4086.641% |
| Pharming Group N.V. | -4.87 Million USD | -5128.87% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -2955.629% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -18098.762% |
| IMV Inc. | -38.67 Million USD | -559.775% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -9175.17% |
| MultiCell Technologies, Inc. | -722.81 USD | -35298941.242% |
| ONE Bio Corp. | 13.68 Million USD | 1964.884% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -332.522% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 7307.486% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -8694.313% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -3737.913% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -851746.287% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -1507.746% |
| Alpha Cognition Inc. | -9.7 Million USD | -2528.843% |
| Enzolytics Inc. | -2.14 Million USD | -11773.837% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 39.973% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -24339.176% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -8639.507% |
| Genscript Biotech Corporation | -415.79 Million USD | 38.636% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 5291.349% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -97385.538% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -10291.53% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -148664.319% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -12626.979% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 2718.897% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -5501.764% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -6710.37% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -25827.973% |
| EV Biologics, Inc. | -483.06 Thousand USD | -52718.272% |
| Q BioMed Inc. | -3.44 Million USD | -7304.917% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -20214.092% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -364.133% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -3179.933% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -13102.095% |
| HST Global, Inc. | -140.9 Thousand USD | -180973.332% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -19005.817% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -22581.451% |
| Halberd Corporation | -75.05 Thousand USD | -339866.689% |
| Resverlogix Corp. | -12.74 Million USD | -1901.294% |
| Cell Source, Inc. | -4.32 Million USD | -5798.834% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -16055.013% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 3912.185% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1464482.975% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -10243.325% |
| Kadimastem Ltd | -3.04 Million USD | -8292.237% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -5919.823% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -140487.376% |
| LadRx Corporation | -3.82 Million USD | -6572.855% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -37041.713% |
| Affymax, Inc. | -15.04 Million USD | -1595.766% |
| Itoco Inc. | -919.14 Thousand USD | -27659.101% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22701.162% |
| Mobile Lads Corp. | -554.55 Thousand USD | -45909.377% |
| International Stem Cell Corporation | -663 Thousand USD | -38383.409% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -6578.931% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1013586.929% |
| Qrons Inc. | -643.67 Thousand USD | -39538.67% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -45080.558% |
| SYBLEU INC | -149.18 Thousand USD | -170931.64% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -11342.101% |
| Rebus Holdings, Inc. | -664 Thousand USD | -38325.452% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -13947.359% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -484597.948% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1254300.197% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -603.538% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -15669.159% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -34574.214% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -8101.382% |
| Neutra Corp. | -229.48 Thousand USD | -111081.074% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -1354.729% |
| PureTech Health plc | -146.19 Million USD | -74.519% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -1087.211% |
| IXICO plc | -1.43 Million USD | -17655.393% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -2588.284% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -109.468% |
| CSL Limited | 3.81 Billion USD | 106.693% |
| Cellectis S.A. | -108.85 Million USD | -134.385% |